Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 4/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.51 |
| ▸ | RORC | P51449 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.48 |
| ▸ | USP7 | Q93009 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16141295 | 1.00 | TACR1 (0.54) | TACR1GPR119RORCPDE4BJAK2 | |
| SCHEMBL16108769 | 1.00 | TACR1 (0.54) | TACR1GPR119RORCPDE4BJAK2 | |
| SCHEMBL4709680 | 1.00 | TACR1 (0.54) | TACR1GPR119RORCPDE4BJAK2 | |
| SCHEMBL3010008 | 0.90 | RORC (0.54) | TACR1GPR119RORCPDE4BJAK2 | |
| SCHEMBL7906244 | 0.90 | RORC (0.54) | TACR1GPR119RORCPDE4BJAK2 | |
| SCHEMBL3010002 | 0.90 | RORC (0.54) | TACR1GPR119RORCPDE4BJAK2 | |
| SCHEMBL30679675 | 0.90 | TACR1 (0.54) | TACR1GPR119RORCJAK2JAK1 | |
| SCHEMBL14921685 | 0.89 | GPR119 (0.52) | TACR1GPR119RORCPDE4BJAK2 | |
| SCHEMBL14921684 | 0.89 | GPR119 (0.52) | TACR1GPR119RORCPDE4BJAK2 | |
| SCHEMBL14934616 | 0.89 | GPR119 (0.52) | TACR1GPR119RORCPDE4BJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| EP-1966137-A2 | PIPERIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007072150-A2 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142389-A1 | PIPERIDINE DERIVATIVES | PFIZER INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142389-A1 | PIPERIDINE DERIVATIVES | CFTR, HDAC10, RPP30 | TACR1 98/4885GPR119 216/4885RORC 341/4885 |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPA1, TRPV3 | TACR1 682/4885GPR119 1898/4885RORC 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.